Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Global Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy) Pipeline Review 2016 - Research and Markets

Research and Markets
Posted on: 24 Oct 16

Research and Markets has announced the addition of the "Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Pipeline Review, H2 2016" report to their offering.

"Leber's Hereditary Optic Neuropathy - Pipeline Review, H2 2016": Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) pipeline therapeutics constitutes close to 11 molecules, out of which approximately 10 molecules are developed by Companies and the remaining by the Universities/Institutes.

Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) is an inherited form of vision loss. This condition usually begins in a person's teens or twenties; rare cases may appear in early childhood or later in adulthood. Males are affected much more often than females. Symptoms include eye pain or discomfort, numbness, tingling and clouding of vision. Predisposing factors include age, tobacco smoke, alcohol, cancer-treating drugs, stress-related chemicals, some antibiotics and cyanogens.

"Leber's Hereditary Optic Neuropathy - Pipeline Review, H2 2016" outlays comprehensive information on the therapeutics under development for Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, that are being developed by Companies/Universities.

It also reviews key players involved in therapeutic development for Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) and features dormant and discontinued projects. Currently, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 3, 3, 1 and 1, respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecule, respectively.

Key Topics Covered:

  1. Introduction
  2. Leber's Hereditary Optic Neuropathy Leber optic atrophy Overview
  3. Therapeutics Development
  4. Pipeline Products for Leber's Hereditary Optic Neuropathy Leber optic atrophy - Overview
  5. Pipeline Products for Leber's Hereditary Optic Neuropathy Leber optic atrophy - Comparative Analysis
  6. Leber's Hereditary Optic Neuropathy Leber optic atrophy - Therapeutics under Development by Companies
  7. Leber's Hereditary Optic Neuropathy Leber optic atrophy - Therapeutics under Investigation by Universities/Institutes
  8. Leber's Hereditary Optic Neuropathy Leber optic atrophy Products Glance
  9. Late-Stage Products
  10. Clinical-Stage Products
  11. Early-Stage Products
  12. Leber's Hereditary Optic Neuropathy Leber optic atrophy - Products under Development by Companies
  13. Leber's Hereditary Optic Neuropathy Leber optic atrophy - Products under Investigation by Universities/Institutes
  14. Leber's Hereditary Optic Neuropathy Leber optic atrophy - Companies Involved in Therapeutics Development
  • Alkeus Pharmaceuticals Inc.
  • Biovista Inc.
  • GenSight Biologics S.A.
  • Ixchel Pharma LLC
  • Khondrion BV
  • Spark Therapeutics Inc.
  • Stealth BioTherapeutics Inc.

For more information about this report visit http://www.researchandmarkets.com/research/p8z6vk/lebers.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161024006347/en/

Business Wire
www.businesswire.com

Last updated on: 24/10/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.